Literature DB >> 19124736

Endogenous 4-1BB ligand plays a critical role in protection from influenza-induced disease.

Gloria H Y Lin1, Bradley J Sedgmen, Theo J Moraes, Laura M Snell, David J Topham, Tania H Watts.   

Abstract

A critical issue during severe respiratory infection is whether it is the virus or the host response that does the most damage. In this study, we show that endogenous 4-1BBL plays a critical role in protecting mice from severe effects of influenza disease. During mild respiratory influenza infection in which virus is rapidly cleared, the inducible costimulatory receptor 4-1BB is only transiently induced on lung T cells and 4-1BB ligand (4-1BBL) is completely dispensable for the initial CD8 T cell response and mouse survival. In contrast, during more severe respiratory influenza infection with prolonged viral load, 4-1BB expression on lung CD8 T cells is sustained, and 4-1BBL-deficient mice show decreased CD8 T cell accumulation in the lungs, decreased viral clearance, impaired lung function, and increased mortality. Transfer of an optimal number of naive Ag-specific T cells before infection protects wild-type but not 4-1BBL-deficient mice from an otherwise lethal dose of influenza virus. Transfer of T cells lacking the proapoptotic molecule Bim extends the lifespan of 4-1BBL-deficient mice by one to three days, suggesting that at least part of the role of 4-1BB/4-1BBL is to prolong effector cell survival long enough to clear virus. Intranasal delivery of 4-1BBL by recombinant adenovirus marginally improves survival of 4-1BBL-deficient mice at low dose, but exacerbates disease at high dose. These findings suggest a rationale for the evolutionary accumulation of inducible costimulatory molecules, thereby allowing the immune system to sustain the expression of molecules such as 4-1BB to a level commensurate with severity of infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19124736     DOI: 10.4049/jimmunol.182.2.934

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement.

Authors:  Kevin M Friedman; Laura E Devillier; Steven A Feldman; Steven A Rosenberg; Mark E Dudley
Journal:  J Immunother       Date:  2011 Nov-Dec       Impact factor: 4.456

Review 2.  CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.

Authors:  Bhushan Dharmadhikari; Meihui Wu; Nur Sharalyn Abdullah; Sakthi Rajendran; Nur Diana Ishak; Emily Nickles; Zulkarnain Harfuddin; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

Review 3.  Modulation of GITR for cancer immunotherapy.

Authors:  David A Schaer; Judith T Murphy; Jedd D Wolchok
Journal:  Curr Opin Immunol       Date:  2012-01-12       Impact factor: 7.486

Review 4.  Gene therapy for ALI/ARDS.

Authors:  Xin Lin; David A Dean
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

Review 5.  Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity.

Authors:  Shahram Salek-Ardakani; Michael Croft
Journal:  J Interferon Cytokine Res       Date:  2010-04       Impact factor: 2.607

Review 6.  Fine-tuning of dendritic cell biology by the TNF superfamily.

Authors:  Leslie Summers deLuca; Jennifer L Gommerman
Journal:  Nat Rev Immunol       Date:  2012-04-10       Impact factor: 53.106

7.  Intrinsic 4-1BB signals are indispensable for the establishment of an influenza-specific tissue-resident memory CD8 T-cell population in the lung.

Authors:  A C Zhou; L E Wagar; M E Wortzman; T H Watts
Journal:  Mucosal Immunol       Date:  2017-01-04       Impact factor: 7.313

8.  The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137+ FOXP3+ Regulatory CD4 T Cells.

Authors:  Bardees M Foda; Ashley E Ciecko; David V Serreze; William M Ridgway; Aron M Geurts; Yi-Guang Chen
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

9.  Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.

Authors:  Gloria H Y Lin; Yuanqing Liu; Thanuja Ambagala; Byoung S Kwon; Pamela S Ohashi; Tania H Watts
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

10.  IL-15 trans-presentation by pulmonary dendritic cells promotes effector CD8 T cell survival during influenza virus infection.

Authors:  Jodi McGill; Nico Van Rooijen; Kevin L Legge
Journal:  J Exp Med       Date:  2010-03-08       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.